Covid-19 vaccine: what if we never found it like HIV AIDS?

[GuyGadebois]

As for glyphosate, nuclear power and GMOs: "it's of no consequence".

[Christophe]

I quote you here because more appropriate Guy: society-and-philosophy / the-end-of-confinement-approach-t16435-80.html # p395865

Nearly 200 mutations in the new coronavirus have already been recorded since the start of the epidemic. Despite this impressive figure, these would be minor on the structure of the virus. However, recent research brings new elements: the dangerousness of these mutations would be variable. Indeed, if most of them have no influence on the very function of the virus, Chinese researchers have shown that certain mutations lead to strains up to 270 times more virulent than others. This would explain why from one region to another, the incidence of the epidemic is not the same.

https://www.ladepeche.fr/2020/05/12/les ... 883873.php

The vaccine track is moving away!

[Christophe]

Too bad this article does not cite the references of the Chinese study !!!

[GuyGadebois]

Too bad this article does not cite the references of the Chinese study !!!

https://www.medrxiv.org/content/10.1101 ... 20060160v2

[Christophe]

Thank you Chef !!

[GuyGadebois]

Thank you Chef !!

From riengue, congue. Té, the link to the full study .pdf:
https://www.medrxiv.org/content/10.1101 ... 2.full.pdf

[Christophe]

Okay, I'm not so confused! Are you shooting or punching?

[Christophe]

Thank you Chef !!

From riengue, congue. Té, the link to the full study .pdf:
https://www.medrxiv.org/content/10.1101 ... 2.full.pdf

Well I saw I read I rin understood! Am too confused

Why are they scribbling jellyfish?

[izentrop]

What are you talking about there

good news about this virus is that it is very genetically stable (unlike HIV for example) and the vaccines currently under development should be effective for several months, even several years. The virus will circulate in waves and for the next ones, we will have the vaccine which should allow us to contain the epidemic "assures the expert in a press release dated April 8.

Vaccines under test
BCG vaccine. Several researchers around the world, especially in France, are working on the BCG anti-tuberculosis vaccine track against the coronavirus. "When there is significant BCG vaccination coverage in a given country, we notice that the severity of the Covid-19 disease is less," said Laurent Lagrost, director of research at Inserm, on LCI. People vaccinated against BCG would therefore not be immunized against SARS-CoV-2 but less at risk of developing a serious form by stimulating the memory of innate immunity (first immunity to come into play against an infection) and thus inducing a 'trained innate immunity' explains Inserm in a press release. The promising results are published in the journal Cell Stem Cell. The Institut Pasteur de Lille will try to set up a clinical trial to verify the hypothesis. This trial will require following the participants for 2 to 3 months to obtain reliable data.
DNA vaccine. The Institut Pasteur works in France on two axes : the accelerated development of a DNA vaccine candidate which is "a technique of protection against diseases by injection of DNA encoding an antigen of interest. The injected DNA elicits a protective immunological response, for example by the production of antibody against the antigen. DNA vaccines have potential advantages over conventional vaccines, including the ability to induce a wider range of types of immune responses. Two candidate antigens have already been designed, based on the S protein (spicule) of the virus, the protein responsible for the "crown" observed on the surface of the coronaviruses at the origin of their name "details the press release from the Institut Pasteur, the April 4. The second axis of work is on the development of an animal model (the mouse) for infection by SARS-CoV-2. "It will not only allow the efficacy of the vaccine to be evaluated, but will also facilitate in vivo studies of SARS-CoV-2." This research is part of the research projects of the REACTing consortium (REsearch and ACTion targeting emerging infectious diseases), coordinated by Inserm.
International collaboration: Sanofi and GSK laboratories announce work on the development of an adjuvanted vaccine against COVID-19, by uniting their technologies. “The combination of a protein antigen (provided by Sanofi) and an adjuvant (which GSK has mastered) is a reliable procedure, used in several vaccines already on the market,” their press release announced on April 14. It consists of the addition of an adjuvant to certain vaccines to strengthen the immune response, and thus creates a stronger and longer lasting immunity against infections than the vaccine without adjuvant. "The two companies plan to launch phase I clinical trials in the second half of 2020 and, if successful and subject to regulatory requirements, complete all stages of development to be able to make this vaccine available by now. the second half of 2021 " announces the press release. "The world today is facing an unprecedented health crisis and it is clear that no company can fix it alone," said Paul Hudson, CEO of Sanofi.
In the United States, the Johnson & Johnson laboratory is looking for potential vaccine candidates and plans to begin clinical studies in humans no later than September 2020. The first batches of a COVID-19 vaccine may be available for emergency use authorization in early 2021. The company is also of biotechnology Moderna has been testing since Monday, March 16, its first vaccine against the new coronavirus (SARS-CoV-2), mRNA-1273, on a voluntary patient. The study, conducted by the United States National Institutes of Health (NIH), is in its first phase. It assesses the safety and immunogenicity of three dose levels of mRNA-1273 (25, 100, 250 μg) administered according to a precise vaccination schedule, out of a total of 45 healthy adults enrolled in the study. The results will not be known for 12 to 13 months. The main objective is to assess the safety and reactogenicity of a two-dose mRNA-1273 vaccination schedule. The secondary objective is to assess the immunogenicity of the SARS-CoV-2 S protein.
In Germany, the Center for Infection Research (DZIF) is working on genetic coding, the use of specific parts of the SARS-CoV-2 virus against which the human body can develop antibodies. "Scientists have identified a suitable building block of the coronavirus - a spike protein - on the surface of the novel coronavirus. This protein is used by the virus to enter human cells. The corresponding gene sequence (i.e. spike protein construction blueprint) will be combined with genetic information from the MVA vector (a harmless vector already used in the smallpox vaccine over 30 years ago) to result in a viral vector which, when is administered as a vaccination, is able to enter human cells and, therefore, produce advanced proteins. As a result, the immune system can identify these proteins as "foreign", which would stimulate an immune response and production specific antibodies and T cells against the spike protein, "details a DZIF press release on March 9. Another vaccine is also with another vector already used in the measles vaccine.
In China, the first clinical trial has started to test a vaccine on 108 volunteers, all from the city of Wuhan where the Covid-19 first appeared. Volunteers between the ages of 18 and 60 received their first injection on Friday March 20, followed for the next six months.
Thank you to Dr Mathieu Lafaurie, infectious disease specialist at Saint-Louis hospital in Paris and to the spokesperson for the service of Pr Didier Raoult, Director of the IHU Méditerranée Infection. https://sante.journaldesfemmes.fr/fiche ... tats-unis/

[Christophe]

Interesting but ...

Beginning of 2021, second half of 2, 2021 to 12 months ... very long deadlines and no certainty ... we will have exceeded 13 million deaths probably by then ...

Please confirm that they cannot find and what about future mutations?

How quickly does the seasonal flu vaccine get done?